Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs16901979
rs16901979
A 0.800 GeneticVariation GWASCAT 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population. 31562322

2019

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE In particular, both homozygous AA and heterozygous CA genotypes of rs16901979, as well as the AA and CA genotypes of rs1447295, were associated with the risk of prostate cancer. 30061842

2018

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk. 29158792

2017

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Significant differences (P < 0.00185) between the two subtypes were observed for rs16901979 (8q24) and rs1859962 (17q24), which were enriched in TMPRSS2:ERG fusion-negative (OR = 0.53, P = 0.0007) and TMPRSS2:ERG fusion-positive PrCa (OR = 1.30, P = 0.0016), respectively. 27798103

2016

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE In summary, the A allele at rs16901979 was associated with the risk of prostate cancer in the Caribbean population of Guadeloupe, confirming its involvement in populations of African descent. 25130587

2016

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Three 8q24 polymorphisms (rs1447295 C>A, rs16901979 C>A, and rs6983267 T>G) have been extensively investigated for their association with prostate cancer (PCa) susceptibility, yet conclusions are contradictory. 26159557

2015

dbSNP: rs16901979
rs16901979
A 0.800 GeneticVariation GWASCAT Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. 26443449

2015

dbSNP: rs16901979
rs16901979
A 0.800 GeneticVariation GWASCAT Two susceptibility loci identified for prostate cancer aggressiveness. 25939597

2015

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE The results of the meta-analyses indicate that rs6983267, rs1447295, rs6983561, rs7837688, rs16901979, and DG8S737 are significantly associated with a higher risk for PCa for at least one race, whereas the variants rs13254738 and rs7000448 are not. 22382457

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE SNPs rs6983561, rs7008482, and rs16901979 were significantly associated with CaP risk in WAs (P < 0.03). 22234922

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE In conclusion, this is the first study showing that prostate cancer risk variants, such as rs16901979, might improve outcome prediction following ADT, thus allowing identification of high-risk patients who might benefit from appropriate adjuvant therapy. 21445969

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE The rs16901979 CA genotype carriers had a higher risk of prostate cancer than the CC genotype. 22583965

2012

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE SNP rs16901979 in region 2 was associated with significantly increased risk of prostate cancer (OR = 1.41, 95% confidence interval [CI] 1.02-1.95, P = 0.04) with the risk stronger in men with early-onset prostate cancer (OR = 2.37, 95% CI 1.40-3.99, P = 0.001). 21557270

2011

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE We demonstrate that trans-acting RNA molecules facilitating resistance to androgen depletion (RAD) in vitro and castration-resistant phenotype (CRP) in vivo of PC contain intergenic 8q24-locus SNP variants (rs1447295; rs16901979; rs6983267) that were recently linked with increased risk of PC. 22067658

2011

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE The variants rs16901979 and rs6983561 at 8q24 are associated with prostate cancer risk in Taiwanese men. 19908238

2010

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Forty-nine tagging SNPs including three previously reported significant variants (rs1447295, rs6983267, rs16901979) and seven variants in the 5' upstream region of the MYC proto-oncogene were tested for association with susceptibility to PC and tumor aggressiveness in 596 histologically verified PC cases and 567 ethnically matched controls. 19562729

2009

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE Two of these 17 SNPs, located at 3p12, and region 2 at 8q24, were significantly associated with prostate cancer risk (P < 0.05), and only SNP rs16901979 at region 2 of 8q24 remained significant after accounting for 20 tests. 19549807

2009

dbSNP: rs16901979
rs16901979
A 0.800 GeneticVariation GWASCAT Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. 19767754

2009

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE There was no joint effect between SNPs rs16901979 A and rs6983267 G. These results confirm the significance of these SNPs in prostate cancer etiology in a previously unstudied population who do not undergo prostate cancer screening and are diagnosed with severe disease. 18768513

2008

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE A meta-analysis across 10 studies including our results of four 8q24 variants (rs1442295 and DG8S737-region 1, rs16901979-region 2, and rs6983267-region 3) and prostate cancer risk demonstrated strong associations across a wide array of study designs and populations. 18231127

2008

dbSNP: rs16901979
rs16901979
A 0.800 GeneticVariation GWASCAT Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. 17401366

2007

dbSNP: rs16901979
rs16901979
0.800 GeneticVariation BEFREE We report that rs7008482, which maps to the 8q24.13 region, is an additional independent prostate cancer risk variant (P = 5 x 10(-4)), and we also replicate the association of rs16901979 with prostate cancer (P = 0.002). 17978284

2007